FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996305968> ?p ?o ?g. }

• W1996305968 endingPage "19875" @default.
• W1996305968 startingPage "19875" @default.
• W1996305968 abstract "By 2013, there was a 40% decline in new paediatric infections compared to 2009. Prevention of mother to child transmission (PMTCT) of HIV continues to reduce the frequency of HIV in infants through wider and earlier implementation of antenatal combination antiretroviral therapy (ART). Post-natally, breastfed infants are now protected from HIV infection through maternal ART and/or infant nevirapine (NVP) [1]. The ultimate aim is the elimination of vertical transmission of HIV. Should HIV infection occur in infants, the focus is on early detection and treatment. The children with HIV early antiretroviral (CHER) trial established the benefit of initiating ART at a median of seven weeks of age [2,3]. The narrative of the Mississippi child focussed attention on very early diagnosis and therapy. This infant, whose mother was diagnosed as HIV-positive in labour, initiated ART 31 hours after delivery. After ART discontinuation from 15 to 21 months of age due to poor adherence, plasma HIV RNA remained undetectable on standard assays until almost four years of age, with only traces of HIV DNA being found using sophisticated assays [4,5]. The main driver of mother to child transmission is the maternal viral load. Although in utero infection has been observed from 12 weeks’ gestation [6], it is likely that the majority occur in the last two months of pregnancy [7]. Therefore, antenatal ART is most effective when commenced by week 20 of pregnancy [8]. Pregnancy is time-limited. Every week of delayed diagnosis increases the risk of vertical transmission. Using data from studies until 2010, Johnson and colleagues calculated that seroconversion late in pregnancy or during breastfeeding contributes 28% of vertical infections, which could be reduced through testing at 32 weeks’ gestation, and at the six-week post-natal visit [9]. Many of these recommendations have now been incorporated in MTCT guidelines, with additional testing in seronegative breastfeeding mothers at three-monthly intervals thereafter recommended [10]. Testing of sexual partners of HIV uninfected pregnant and breastfeeding women may further prevent new acquisition. While the rapid antibody tests are effective, the window period for developing sufficient antibodies for a positive test is between two and eight weeks, with almost 100% being positive after 12 weeks [11]. A new innovation is the point of care virological test, which will substantially increase diagnosis of acute HIV [12]. Dried blood spots offer an appropriate alternative for more resource-constrained settings [13]. Expanded testing should be offered for women where significant risk of acute HIV is identified, for example, those presenting with acute seroconversion illness or in high prevalence settings (Table 1 – see suggested approach to improving maternal diagnosis and ART success). For new HIV diagnosis in late pregnancy or labour, there is a possibility of reducing risk of vertical transmission through enhanced post-exposure prophylaxis. A randomized study of post-exposure prophylaxis for infants born to women from high prevalence settings where HIV was diagnosed late in pregnancy and who received no antenatal ARVs, has contributed many insights. The main objective was to determine the best post-exposure regimen for infants at extremely high risk for vertical HIV infection. Two antiretrovirals (ARVs) (zidovudine [ZDV] for six weeks plus three doses of NVP in the first week or three ARVs (ZDV, lamivudine [LMV] and nelfinavir) for two weeks performed equally well and were superior to ZDV given for six weeks in formula-fed infants [14]. Given the superior efficacy of three ARVS compared to two ARVs for treatment, many would have hoped that the three-drug regimen would be better. Reasons for equivalence include inability to achieve therapeutic exposure for nelfinavir in 46% of infants, although nearly all had trough levels above 0.05 µg/ml, 10 times the upper limit of nelfinavir IC50 for wild type HIV [15]. Also, the standard duration of post-exposure prevention is four weeks, rather than the two weeks used in this study [16]. Post-exposure prophylaxis for 28 days rather than a shorter period is supported by rhesus macaque studies after simian immunodeficiency virus infection [17,18]. A recent cohort analysis from Europe showed that a three-ARV regimen for 28 days in post-exposure prophylaxis is being used more frequently in circumstances where there is a high risk of vertical transmission [19]. This strategy is being widely adopted subsequent to the report of the Mississippi baby [4] and experience in Canada [20]. In the post-exposure prophylaxis study by Nielsen-Saines et al., a polymerase chain reaction (PCR) test on the first day of life showed in utero infection in 5.7% of infants, illustrating the importance of an immediate PCR when the risk of transmission is high. There is a growing concern that both the accuracy of diagnostic testing and relying on a single test in the presence of ARV exposure are insufficient, leading to a false sense of security. In one report, a PCR at 4–6 weeks of age in formula-fed infants missed 32% of infections found at three months of age. Other studies have confirmed the inaccuracy of a single PCR at 4–6 weeks of age [21,22]. Point of care virological testing may be useful on the first day of life particularly where there is a high transmission risk but is not essential provided that at least two blood specimens are drawn for PCR in the first few days of life and triple ARV prophylaxis is initiated as soon as possible after birth. The latter should then be continued if the infant is HIV-infected. Also, for breastfed infants regular virological testing of the infant is essential until the infant is fully weaned (see Table 2). PMTCT approaches in high prevalence settings require urgent adaptation to improve early infant diagnosis for the prevention and management of HIV. Both authors received support from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1AI069521. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Both authors have no competing interests. Mark F Cotton wrote the manuscript; Helena Rabie gave input, reviewed the manuscript and approved the final version." @default.
• W1996305968 created "2016-06-24" @default.
• W1996305968 creator A5011540954 @default.
• W1996305968 creator A5051728617 @default.
• W1996305968 date "2014-01-01" @default.
• W1996305968 modified "2023-10-03" @default.
• W1996305968 title "Universal children's day - let's improve current interventions to reduce vertical transmission of HIV now" @default.
• W1996305968 cites W1955224405 @default.
• W1996305968 cites W2001513054 @default.
• W1996305968 cites W2054937433 @default.
• W1996305968 cites W2059762016 @default.
• W1996305968 cites W2061691913 @default.
• W1996305968 cites W2090432953 @default.
• W1996305968 cites W2112111604 @default.
• W1996305968 cites W2122986037 @default.
• W1996305968 cites W2129035077 @default.
• W1996305968 cites W2130560337 @default.
• W1996305968 cites W2135390958 @default.
• W1996305968 cites W2136162179 @default.
• W1996305968 cites W2141357379 @default.
• W1996305968 cites W2146682154 @default.
• W1996305968 cites W2147275987 @default.
• W1996305968 cites W2165315339 @default.
• W1996305968 cites W2277283611 @default.
• W1996305968 doi "https://doi.org/10.7448/ias.17.1.19875" @default.
• W1996305968 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4240851" @default.
• W1996305968 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25416416" @default.
• W1996305968 hasPublicationYear "2014" @default.
• W1996305968 type Work @default.
• W1996305968 sameAs 1996305968 @default.
• W1996305968 citedByCount "1" @default.
• W1996305968 countsByYear W19963059682016 @default.
• W1996305968 crossrefType "journal-article" @default.
• W1996305968 hasAuthorship W1996305968A5011540954 @default.
• W1996305968 hasAuthorship W1996305968A5051728617 @default.
• W1996305968 hasBestOaLocation W19963059681 @default.
• W1996305968 hasConcept C119599485 @default.
• W1996305968 hasConcept C127413603 @default.
• W1996305968 hasConcept C148043351 @default.
• W1996305968 hasConcept C159047783 @default.
• W1996305968 hasConcept C159110408 @default.
• W1996305968 hasConcept C187212893 @default.
• W1996305968 hasConcept C27415008 @default.
• W1996305968 hasConcept C3013748606 @default.
• W1996305968 hasConcept C41008148 @default.
• W1996305968 hasConcept C512399662 @default.
• W1996305968 hasConcept C71924100 @default.
• W1996305968 hasConcept C761482 @default.
• W1996305968 hasConcept C76155785 @default.
• W1996305968 hasConceptScore W1996305968C119599485 @default.
• W1996305968 hasConceptScore W1996305968C127413603 @default.
• W1996305968 hasConceptScore W1996305968C148043351 @default.
• W1996305968 hasConceptScore W1996305968C159047783 @default.
• W1996305968 hasConceptScore W1996305968C159110408 @default.
• W1996305968 hasConceptScore W1996305968C187212893 @default.
• W1996305968 hasConceptScore W1996305968C27415008 @default.
• W1996305968 hasConceptScore W1996305968C3013748606 @default.
• W1996305968 hasConceptScore W1996305968C41008148 @default.
• W1996305968 hasConceptScore W1996305968C512399662 @default.
• W1996305968 hasConceptScore W1996305968C71924100 @default.
• W1996305968 hasConceptScore W1996305968C761482 @default.
• W1996305968 hasConceptScore W1996305968C76155785 @default.
• W1996305968 hasFunder F4320332161 @default.
• W1996305968 hasFunder F4320337355 @default.
• W1996305968 hasIssue "1" @default.
• W1996305968 hasLocation W19963059681 @default.
• W1996305968 hasLocation W19963059682 @default.
• W1996305968 hasLocation W19963059683 @default.
• W1996305968 hasLocation W19963059684 @default.
• W1996305968 hasOpenAccess W1996305968 @default.
• W1996305968 hasPrimaryLocation W19963059681 @default.
• W1996305968 hasRelatedWork W1945359667 @default.
• W1996305968 hasRelatedWork W1973460911 @default.
• W1996305968 hasRelatedWork W2049655029 @default.
• W1996305968 hasRelatedWork W2096903645 @default.
• W1996305968 hasRelatedWork W2140033339 @default.
• W1996305968 hasRelatedWork W2409957712 @default.
• W1996305968 hasRelatedWork W2410491650 @default.
• W1996305968 hasRelatedWork W2465215300 @default.
• W1996305968 hasRelatedWork W2604682584 @default.
• W1996305968 hasRelatedWork W4253675151 @default.
• W1996305968 hasVolume "17" @default.
• W1996305968 isParatext "false" @default.
• W1996305968 isRetracted "false" @default.
• W1996305968 magId "1996305968" @default.
• W1996305968 workType "article" @default.